The Contract Development and Manufacturing Organization (CDMO) sector has experienced a boom in recent years as Big Pharma has shifted its attention to its core R&D activities and outsourced other supply chain components, including manufacturing, to independent CDMOs. Additionally, it is no surprise that the worldwide CDMO market is anticipated to increase from USD 81 billion in 2020 to USD 159 billion by 2027 (Valuates Reports) due to the development of biotechs around the world, the majority of which lack the internal manufacturing capacity to make their own medications.
Through CDMO outsourcing, companies can cut significant capital expenditures for developing internal technical capabilities and concentrate on strategic and commercial priorities. Due to the significant demand for end-to-end services in large pharmaceutical companies, execution costs, increasing pricing pressures, and pipeline issues, CDMO is therefore destined to share the majority of pharma/ biopharma production stage activities.
In this edition of Pharma Tech Outlook APAC, we present the list of the Top 10 CDMOs in APAC– 2022. Bushu Pharmaceuticals Solution, Chimebiologics Service, LinkChem, and ST PHARM are some of the prominent CDMOs in the region. We also bring to you thought leadership articles and exclusive insights from expert CIOs and CXOs - Dr. Ammar Raza, Regional Medical Director- Middle East and Africa, Allergan Aesthetics, AbbVie, Alexander Bernikov, Medical Director, Clinical Development (Uro)-Oncology, Jiangsu Hengrui Pharmaceuticals, Jessica Rayser, Associate Director of Product Management, Charles River Laboratories presenting their views and opinions on how organizations can incorporate changes. We hope the valuable insights from industry thought leaders and the CDMOs featured in this edition help you make informed decisions for your organization.
Let us know your thoughts!
